B. Riley Begins Coverage on Endo International (ENDP)

B. Riley assumed coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a research report report published on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $10.00 target price on the stock.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald lowered their target price on Endo International from $9.00 to $7.00 and set a neutral rating on the stock in a research note on Friday, November 10th. ValuEngine downgraded Endo International from a buy rating to a hold rating in a research note on Friday, February 2nd. BidaskClub upgraded Endo International from a sell rating to a hold rating in a research note on Tuesday, December 12th. Guggenheim assumed coverage on Endo International in a research note on Tuesday, December 12th. They issued a neutral rating and a $8.50 target price on the stock. Finally, Citigroup lowered their target price on Endo International from $9.00 to $7.00 and set a neutral rating on the stock in a research note on Friday, November 10th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $10.51.

Shares of Endo International (NASDAQ:ENDP) traded up $0.41 on Wednesday, hitting $6.73. The stock had a trading volume of 4,968,900 shares, compared to its average volume of 6,097,896. Endo International has a 1 year low of $5.77 and a 1 year high of $14.45. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78. The stock has a market capitalization of $1,411.34, a P/E ratio of -0.30, a price-to-earnings-growth ratio of 2.20 and a beta of 0.29.

A number of hedge funds have recently modified their holdings of ENDP. Ameriprise Financial Inc. boosted its position in Endo International by 4.9% during the second quarter. Ameriprise Financial Inc. now owns 581,552 shares of the company’s stock worth $6,497,000 after purchasing an additional 27,414 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Endo International by 18.7% during the second quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company’s stock worth $4,447,000 after purchasing an additional 62,822 shares in the last quarter. Nomura Holdings Inc. purchased a new position in Endo International during the second quarter worth approximately $745,000. Piedmont Investment Advisors LLC boosted its position in Endo International by 43.4% during the second quarter. Piedmont Investment Advisors LLC now owns 59,211 shares of the company’s stock worth $661,000 after purchasing an additional 17,928 shares in the last quarter. Finally, Diamond Hill Capital Management Inc. boosted its position in Endo International by 46.8% during the third quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock worth $6,138,000 after purchasing an additional 228,426 shares in the last quarter. Institutional investors own 92.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “B. Riley Begins Coverage on Endo International (ENDP)” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/02/15/b-riley-begins-coverage-on-endo-international-endp.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply